TrialInternational journal of clinical pharmacy2022

Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Yuan Jiang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.